Zim Laboratories Ltd Approves Allotment of ESOP Shares Under ZIM Laboratories Employee Stock Option Scheme
Zim Laboratories Ltd announced that its Board of Directors approved the allotment of a block of employee stock options on April 18, 2026. The allotment was made to eligible employees of the Subsidiary Company under the ‘ZIM Laboratories Employee Stock Option Scheme (ESOS 2023)’.The company approved the allotment of 48,726 Equity Shares, each having a face value of INR 10/-. These shares were issued upon the exercise of vested options by the eligible employee.
The issuance of the ESOP shares resulted in an increase in the company’s paid-up equity share capital. Prior to this allotment, the paid-up equity share capital stood at Rs. 53,50,03,110/-. Following the allotment, the total paid-up equity share capital increased to Rs. 53,54,90,370/-.
The updated capital structure details are as follows:
| Description | Shares (Units) | Face Value per Share | Total Capital (INR) |
|---|---|---|---|
| Previous Paid-up Capital | 5,35,00,311 | Rs. 10/- | 53,50,03,110/- |
| Allotment of ESOP Shares | 48,726 | Rs. 10/- | N/A |
| New Paid-up Capital | 5,35,49,037 | Rs. 10/- | 53,54,90,370/- |
The shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Key financial details related to the share transaction include the following:
| Detail | Value |
|---|---|
| Total Shares Allotted | 48,726 Equity shares |
| Exercise Price per Share | Rs. 77.40/- |
| Premium per Share | Rs. 67.40/- |
| Total Issued Shares after this issue | 5,35,49,037 |
The allotment of shares ranks pari-passu with the company's existing equity shares, meaning all equity shares, including those allotted through the stock options, possess equal status.
Stock Price Movement
Zim Laboratories Ltd shares finished the Friday session at ₹79.72, closing up a strong 4.89%. Throughout the trading day, the stock traded across a notable intraday range, bouncing between ₹75.35 and ₹80.00.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.